In 2025, the number of children receiving a drug promoted — but unproven — for autism treatment grew, especially toward the end of the year. A new study suggests the late rise was influenced by a Trump administration announcement.
At a White House briefing on September 22, 2025, President Trump touted the drug leucovorin as a potential therapeutic for autism. The week before the announcement, roughly 5 children per 100,000 received leucovorin via a prescription in the United States. The week of the announcement, the pharmacy dispensing rate climbed to roughly 7 children per 100,000. By the end of the year, the rate rose to 8 children per…
Read the full article at SCIENCENEWS.ORG
